Biểu đồ giá cổ phiếu BMRN
BMRN Dự đoán giá cổ phiếu
BioMarin Pharmaceutical Inc
$50.2
0.78%
$0.39
Khi đóng cửa: May 20, 16:00:00 GMT-4
$52.07
3.72%
$1.87
Phiên sau giờ: May 20, 20:00:00 GMT-4
Quay lại
BioMarin Pharmaceutical Inc (BMRN) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$49.81
Giá mở cửa
$49.81
Phạm vi ngày
$49.41 - $52.07
Phạm vi 52 tuần
$50.76 - $66.27
Khối lượng
2.1M
Khối lượng trung bình
2.0M
Tỷ suất cổ tức
--
EPS (TTM)
1.76
Vốn hóa thị trường
$10.0B
BMRN là gì?
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.
